OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Obesity-driven phosphatidylethanolamine dysregulation impairs neuroimmune crosstalk and accelerates Alzheimer’s pathogenesis	597
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	329
Molecular hallmarks of excitatory and inhibitory neuronal resilience to Alzheimer’s disease	260
Tau interactome and RNA binding proteins in neurodegenerative diseases	247
Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer’s disease through disrupted regulated intramembrane proteolysis	232
LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome	207
Altered trafficking of Kv1-Kvβ2 leads to neuronal hyperexcitability and memory deficits in amyloid-β pathology	184
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	182
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	166
Synaptic control of retinal ganglion cell survival and axon regeneration	159
Regulation of the hippocampal translatome by Apoer2-ICD release	152
Retraction Note: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5– implications for dementia with lewy bodies	137
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	132
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways	128
Death-associated protein kinase 1-dependent SENP1 degradation increases tau SUMOylation and leads to cognitive dysfunction in a mouse model for tauopathy	121
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	110
Microglia sensing of peripheral signals that bridge the brain and body	107
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	104
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	102
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	101
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	101
Organelle stress in NLRP3 inflammasome: a central mediator of neurodegenerative diseases	100
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	97
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	94
Recombinant cathepsins B and L promote α-synuclein clearance and restore lysosomal function in human and murine models with α-synuclein pathology	94

Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	90
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	86
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	83
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	81
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	75
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	75
Multi-omics insights into GBA1-associated Parkinson’s disease: interplay of genomics, transcriptomics, proteomics, and lipidomics	74
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	71
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	70
In Memoriam of Edward H. Koo, MD 1954–2025	69
Autophagic impairment in sleep–wake circuitry is linked to sleep loss at the early stages of Alzheimer’s disease	68
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	68
Entering the era of precision medicine to treat amyotrophic lateral sclerosis	67
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	65
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	65
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	63
Impaired nucleocytoplasmic transport in SOD1-mediated ALS	63
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	61
Combination therapy using GDNF and cell transplant in Parkinson’s disease	61
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	60
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	59
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	59
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	59
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	57
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	56
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	56
Plasma platelet-derived growth factor receptor-β decrease correlates with blood-brain barrier damage in Alzheimer’s disease	56
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	55
Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes	54
Using mass spectrometry to validate mouse models of tauopathy	54
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	53
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	53
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease	52
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	52
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease	51
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	51
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	51
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	50
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration	50
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	50
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	49
The endotoxin hypothesis of Alzheimer’s disease	49
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease	49
Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases	48
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	47
Diagnostic biomarkers for α-synucleinopathies- state of the art and future developments: a systematic review	47
APOE genotype influences on the brain metabolome of aging mice – role for mitochondrial energetics in mechanisms of resilience in APOE2 genotype	47
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	46
Mechanisms of astrocyte aging in reactivity and disease	46
Sex specific molecular networks and key drivers of Alzheimer’s disease	46

Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	46
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	44
Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’	44
The Hippo signaling pathway as a therapeutic target in Alzheimer’s disease	44
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	43
Interplay between astrocyte reactivity and APOE ε4 status is associated with accelerated pTau-related tau pathology in Alzheimer’s disease	43
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	43
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	42
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	41
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	41
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	41
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	40
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	39
Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease	38
Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology	38
Modulation of O-GlcNAc cycling influences α-synuclein amplification, degradation, and associated neuroinflammatory pathology	38
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	37
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	37
Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies	37
The molecular fidelity of Aβ pathology in 5xFAD and AppNL−FPsen1P117L mice revealed by cryo-EM	37
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	36
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	36
Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson’s and other related neurodegenerat	36
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	36
Blood platelet factor 4: the elixir of brain rejuvenation	36
Proteomic landscape of Alzheimer’s disease: emerging technologies, advances and insights (2021 – 2025)	36
Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature	35
Molecular characterization of humanized APOE mouse models reveals source and genotype dependent differences	35
Seeding activity of skin misfolded tau as a biomarker for tauopathies	35
TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis	35